TERMINATION AND REVISED RELATIONSHIP AGREEMENTTermination and Revised Relationship Agreement • July 19th, 2012 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Termination and Revised Relationship Agreement (this “Agreement”) is entered into as of the 17th day of July 2012 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Purdue Pharmaceutical Products L.P., a Delaware limited partnership (“Purdue”).
TERMINATION AND REVISED RELATIONSHIP AGREEMENTTermination and Revised Relationship Agreement • July 19th, 2012 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Termination and Revised Relationship Agreement (this “Agreement”) is entered into as of the 17th day of July 2012 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Mundipharma International Corporation Limited, a Bermuda corporation having its principal office at Mundipharma House, 14 Par-la-Ville Road, P.O. Box HM 2332, Hamilton HM JX, Bermuda (“MICL”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 19th, 2012 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) dated as of July 17, 2012 (“Effective Date”) is between Infinity Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Purdue Pharma L.P. (the “Purchaser”) and, solely with respect to Sections 4 through 10 herein, Beacon Company (“Beacon”) and Rosebay Medical Company L.P. (“Rosebay” and, together with the Purchaser and Beacon, the “BRP Entities”).
